Glycoengineering of EphA4 Fc leads to a unique

Glycoengineering of EphA4 Fc leads to a unique, long-acting and ...

Eph receptors have emerged as targets for therapy in both neoplastic and non-neoplastic disease, however, particularly in non-neoplastic ...

Glycoengineering of EphA4 Fc leads to a unique, long ... - PubMed

We report a unique glycoengineering approach to enhance the half-life of EphA4 Fc. Progressive deletion of three demonstrated N-linked sites in ...

(PDF) Glycoengineering of EphA4 Fc leads to a unique, long-acting ...

ArticlePDF Available. Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. December 2017 ...

Glycoengineering of EphA4 Fc leads to a unique, long-acting ... - OUCI

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist · Abstract · List of references · Publications ...

Holdings: Glycoengineering of EphA4 Fc leads to a unique, long ...

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Abstract Eph receptors have emerged as ...

Glycoengineering of EphA4 Fc leads to a unique, long-acting and ...

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Decreased signalling of EphA4 improves functional performance ...

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Sci. Rep. 2017;7:6519 ...

Eph receptor signaling complexes in the plasma membrane

], and a unique N-glycosylation site in the EPHA2 FN1–FN2 linker ... 119. Pegg, C.L. ... Glycoengineering of EphA4 Fc leads to a unique ...

Early Blockade of EphA4 Pathway Reduces Trigeminal Neuropathic ...

EphA4-Fc, a soluble chimeric fusion protein of the EphA4 receptor, has been shown to block the activation of the endogenous EphA4 receptor by ...

EPHA4 Membrane Protein Introduction - Creative Biolabs

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Scientific Reports. 2017, 7(1): 6519 ...

Enhancing pharmacokinetic and pharmacodynamic properties of ...

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Sci. Rep., 7 (2017), pp. 1-11, 10.1038 ...

Glycosylation articles within Scientific Reports - Nature

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Cassandra L. Pegg; , Leanne T. Cooper ...

Role of EphA4 in Mediating Motor Neuron Death in MND - MDPI

EphA4 belongs to the A subgroup of Eph receptors and is well known as a pan-receptor that can widely bind, albeit with varying affinities, to all ephrin ligands ...

Bibliome.ai SPR c.600T>C ;(p.P200=)

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Scientific Reports. Pegg, Cassandra L CL ...

OUCI

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Cassandra L. Pegg, Leanne T. Cooper, ...

Receptor-binding domain of ephrin-A1: Production in bacterial ...

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist ... Avoid common mistakes on ...

Therapeutic potential of targeting the Eph/ephrin signaling complex

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Sci Rep 7:6519. Petty A, Idippily N ...

Recombinant EPHA4 (570-986) Protein - Molecular Depot

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist Sci Rep. 2017 Jul 26;7(1):6519. 4: Shi L ...

Enhancing pharmacokinetic and pharmacodynamic properties of ...

three N-linked glycosylation sites in the EphA4 sequence (but not the. Fc ... Gorman, A.W. Boyd, Glycoengineering of EphA4 Fc leads to a unique, long-.

Accumulation of the inhibitory receptor EphA4 may prevent ...

We suggest that a combination of EphA4 accumulation in the injured axons and up-regulation of ephrinB2 in the surrounding astrocytes leads to retraction of ...